Characteristics of medicine use for children with asthma in China: a nationwide population-based study

BMC Pediatrics

Research

Kunling Shen¹  Adong Shen¹  Baoping Xu¹  Huasong Zeng²  Ping Wu³ 

[1] China National Clinical Research Center of Respiratory Diseases, Respiratory Department of Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, No. 56 Nan Li Shi Road, Xicheng District, 100045, Beijing, China;Department of Allergy, Immunology and Rheumatology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, No. 318 Renmin Middle Road, Yuexiu District, 510120, Guangzhou, Guangdong, China;Department of Allergy, Immunology and Rheumatology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, No. 318 Renmin Middle Road, Yuexiu District, 510120, Guangzhou, Guangdong, China;China National Clinical Research Center of Respiratory Diseases, Respiratory Department of Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, No. 56 Nan Li Shi Road, Xicheng District, 100045, Beijing, China;

关键词: Pediatrics;    Asthma;    Medication;    Healthcare insurance data;   

DOI  :  10.1186/s12887-022-03720-5

 received in 2021-09-15, accepted in 2022-10-30,  发布年份 2022

来源: Springer

【 摘 要 】

ObjectiveTo analyze the asthma medication use in Chinese children of different age groups, regions, and levels of cities in China, based on the 2015 Healthcare Insurance Data in China.MethodsThe China Healthcare Insurance Research Association (CHIRA) database was searched for children from 0 to 14 years old diagnosed as asthma based on the “J45” and “J46” coded in ICD-10. A cross-sectional study design was employed.ResultsA total of 308,550 children were identified, all of whom were treated under the coverage of healthcare insurance. Among them, 2,468 children were eligible for inclusion in the present study. Compared with the current status of asthma care in European and American countries, under the guidelines for the diagnosis and treatment of asthma in China, the use percentages of ICS and short-acting β2 receptor agonist in children with asthma in China were lower, but the use percentages of oral corticosteroids, long-acting β2 receptor agonist, and theophylline (especially intravenous theophylline) were higher, especially in the Central and West China.ConclusionThe asthma medication use was attributed to many factors, thus efforts are still needed to further popularize the GINA programs and China's guidelines for asthma diagnosis and treatment, especially in the Central and West China.

【 授权许可】

CC BY   
© The Author(s) 2022

【 图 表 】

12982_2022_119_Article_IEq40.gif

Fig. 1

12982_2022_119_Article_IEq37.gif

Fig. 2

Fig. 1

12982_2022_119_Article_IEq31.gif

12982_2022_119_Article_IEq29.gif

12982_2022_119_Article_IEq21.gif